Cytokine Release Syndrome ManagementMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Has the Cytokine Release Syndrome Management Market Growth Performance Trended Historically, And What Lies Ahead?
The market for managing cytokine release syndrome has seen substantial growth in recent years. The market size is projected to increase from $22.32 billion in 2024 to $23.83 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. This growth during the historical period can be associated with increased spending on healthcare, an increase in awareness, lifestyle modifications, higher disposable income, adoption of personalized medicine methods, and the rise in the utilization of specific targeted therapies.
There is an anticipated robust growth for the cytokine release syndrome management market size in the forthcoming years. It’s predicted to hit a value of $30.69 billion by 2029, climbing at a compound annual growth rate (CAGR) of 6.5%. Factors propelling this projected growth within this forecast timeline include an escalated demand for diagnostic tools and treatments, increased government investment, surges in demand for effective therapies, an ageing population, and the proliferation of initiatives from both public and private entities. The period is also expected to witness trends like minimally invasive breast biopsy devices, strategic alliances and cooperations, antibiotic infusion services at home, the rise of innovative drug delivery systems, and the adoption of electronic health records in monitoring infections.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Cytokine Release Syndrome Management Market?
The growth of the cytokine release syndrome management market is anticipated to be fueled by the growing utilization of targeted therapies. These therapies are medications or treatments explicitly aimed at hindering the proliferation and metastasis of cancer by interacting with molecular targets linked with tumor genesis. The appeal of these targeted therapies lies in their heightened accuracy towards cancer cells while lessening harm to healthy cells, advancing treatment efficacy, and mitigating adverse effects in comparison to conventional therapies. Management of cytokine release syndrome is crucial in enhancing targeted therapies as it regulates intense inflammatory responses, thereby increasing the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, the American Society of Gene and Cell Therapy, a US-based gene and cell therapy institution, reported in January 2024 that there was a 10% increase in gene therapies in Phase III clinical trials in the final quarter of 2023, the first quarterly growth of this nature since the third quarter of 2022. Consequently, the expanding adoption of targeted therapies is catalyzing the growth of the cytokine release syndrome management market.
Which Primary Segments of the Cytokine Release Syndrome Management Market Are Driving Growth and Industry Transformations?
The cytokine release syndrome management market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab, Other Monoclonal Antibodies
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone, Other Corticosteroids
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin, Other Types of Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors, Other Targeted Agents
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
Which Regions Are Key Players in the Growth of the Cytokine Release Syndrome Management Market?
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Cytokine Release Syndrome Management Market?
Major corporations active in the management market for cytokine release syndrome are concentrating on implementing clinical studies to create novel treatments, such as host-directed small molecule drugs, which will control immune response and downplay the intensity of the cytokine storms without jeopardizing the body’s capability to fend off infections or cancer. A host-directed small molecule drug is a compound of low molecular weight that targets the host’s immune signaling pathways to inhibit excessive cytokine production, hence aiding in the management of cytokine release syndrome (CRS) by averting overactivation of the immune system. For instance, in April 2025, US-based biotech company CytoAgents Inc, revealed the successful conclusion of the initial dose-escalation group in its CTO1681 Phase 1b/2a clinical trial, a host-directed small molecule drug designed to prevent and treat CRS in patients undergoing CAR T-cell therapy. This experimental treatment displayed a preferable safety profile, without any dose-limiting toxicities or hindrance to CAR T-cell performance. To establish the recommended dose for the next phase, the trial, which utilises a six dose-escalation system, is carried out to measure the safety, endurance, and initial effectiveness of CTO1681.
View the full report here:
What Parameters Are Used to Define the Cytokine Release Syndrome Management Market?
Cytokine release syndrome (CRS) management involves medical strategies to control the excessive immune response caused by an overproduction of cytokines, often seen in conditions such as CAR-T cell therapy or certain infections. It includes the use of medications such as corticosteroids and cytokine inhibitors, supportive care, and sometimes intensive monitoring to prevent severe complications. This management is crucial in reducing the risk of severe organ damage and improving patient outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
